Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | ADH1B | P00325 | 1/20 | 0.45 |
| ▸ | ADH1C | P00326 | 1/20 | 0.45 |
| ▸ | ADH1A | P07327 | 1/20 | 0.45 |
| ▸ | ADH4 | P08319 | 1/20 | 0.45 |
| ▸ | ADH7 | P40394 | 1/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FDPS | P14324 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5684592 | 1.00 | OPRM1 (0.46) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL28206542 | 1.00 | OPRM1 (0.46) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL5683936 | 1.00 | OPRM1 (0.46) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL2129063 | 1.00 | OPRM1 (0.46) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL20640390 | 1.00 | OPRM1 (0.46) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL17956344 | 1.00 | OPRM1 (0.46) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL10987570 | 1.00 | OPRM1 (0.46) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL10741611 | 1.00 | OPRM1 (0.46) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL5683987 | 1.00 | OPRM1 (0.46) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL28271640 | 1.00 | OPRM1 (0.46) | OPRM1ADH1BADH1CADH1AADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| US-20230073802-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2023-03-09 | — | — | US | claimed |
| US-20220387351-A1 | Compositions and Methods Related to Organic Oxides | Natural Extraction Systems, LLC | 2022-12-08 | — | — | US | claimed |
| US-20220387376-A1 | Compositions Comprising Cannabinoid Molecules that are Dissolved in Water-Miscible Solvents | NATURAL EXTRACTION SYS LLC (US) | 2022-12-08 | — | — | US | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158714-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021087291-A1 | COMPOSITIONS AND METHODS RELATED TO ORGANIC OXIDES | Natural Extraction Systems, LLC (US) | 2021-05-06 | — | — | WO | claimed |
| WO-2021076936-A1 | COMPOSITIONS COMPRISING CANNABINOID MOLECULES THAT ARE DISSOLVED IN WATER-MISCIBLE SOLVENTS | Natural Extraction Systems, LLC (US) | 2021-04-22 | — | — | WO | claimed |
| WO-2021041637-A1 | COMPOSITIONS COMPRISING CANNABINOID IONS DISSOLVING IN GLYCEROL | Natural Extraction Systems, LLC (US) | 2021-03-04 | — | — | WO | claimed |
| WO-2024147345-A1 | COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES, NEGATIVE ELECTRODE FOR LITHIUM ION BATTERIES, LITHIUM ION BATTERY, AND METHOD FOR PRODUCING COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES | ＡＰＢ株式会社 | 2024-07-11 | — | — | WO | disclosed |
| EP-4157360-B1 | TCDTA-DERIVED FE(III) COMPLEXES FOR USE IN MAGNET RESONANCE IMAGING WITH LIVER AND KIDNEY EXCRETION | UNIV BERLIN CHARITE (DE) | 2024-02-28 | — | — | EP | disclosed |
| WO-2023204215-A1 | ELECTRODE COMPOSITION FOR LITHIUM ION BATTERIES, COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES, METHOD FOR PRODUCING COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES, NEGATIVE ELECTRODE FOR LITHIUM ION BATTERIES, AND LITHIUM ION BATTERY | ＡＰＢ株式会社 | 2023-10-26 | — | — | WO | disclosed |
| WO-2023191032-A1 | ELECTRODE FOR LITHIUM-ION BATTERY, AND LITHIUM-ION BATTERY | ＡＰＢ株式会社 | 2023-10-05 | — | — | WO | disclosed |
| US-20230317953-A1 | COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES, NEGATIVE ELECTRODE FOR LITHIUM ION BATTERIES, LITHIUM ION BATTERY, AND METHOD FOR PRODUCING COATED NEGATIVE ELECTRODE ACTIVE MATERIAL PARTICLES FOR LITHIUM ION BATTERIES | APB CORPORATION (JP) | 2023-10-05 | — | — | US | disclosed |
| US-5385693-A | Having rapid response and low phase transition temperature | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1995-01-31 | — | — | US | disclosed |
| EP-0357372-B1 | Optically active ester derivatives, preparation process thereof, liquid crystal materials and a light switching element | SUMITOMO CHEMICAL CO (JP) | 1994-11-17 | — | — | EP | disclosed |
| US-5264151-A | Optically active ester derivatives, preparation process thereof, liquid crystal materials and a light switching element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-11-23 | — | — | US | disclosed |
| US-5124070-A | High speed response | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-06-23 | — | — | US | disclosed |
| EP-0357372-A2 | Optically active ester derivatives, preparation process thereof, liquid crystal materials and a light switching element | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387376-A1 | Compositions Comprising Cannabinoid Molecules that are Dissolved in Water-Miscible Solvents | CNR2, CNR1, PHOSPHO1 | OPRM1 63/4885ADH1B 1702/4885ADH1C 109/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | OPRM1 3826/4885ADH1B 1571/4885ADH1C 4690/4885 |
| US-20220387351-A1 | Compositions and Methods Related to Organic Oxides | LPO, SLCO2A1, SLCO2B1 | OPRM1 26/4885ADH1B 926/4885ADH1C 3333/4885 |
| US-20230073802-A1 | COMPOSITIONS AND METHODS RELATED TO CANNABINOID ANIONS | CNR2, CNR1, FAAH | OPRM1 12/4885ADH1B 2176/4885ADH1C 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.